Orakl Oncology closed an oversubscribed $34M Series A for a platform that predicts how real tumors respond to drugs before a trial starts, taking total funding to $50M. Norrsken VC and Singular co-led.
A 2023 spin-out of Gustave Roussy, the Paris company grows patient-derived organoids, miniature models of individual cancers, and screens them against candidate compounds before layering genomic and phenotypic data onto each patient’s clinical history.
Virtual patients built from living tissue
Norrsken’s label for those assembled cohorts: virtual cancer patients. Databases cannot supply these measurements; they come from patient samples, lab infrastructure and hospital partnerships, with every experiment adding proprietary data tying biology, clinical record and observed response.
Two products carry the business. O-Predict handles response prediction: tumor shrinkage, progression-free and overall survival sit inside its forecasts, biomarkers separate likely responders, and combinations get weighed against benefit-risk. O-Target hunts drug targets.
What the SCOPE results actually show
An April preprint on SCOPE, its Screening-to-Clinical Outcome Prediction Engine, stays unpeer reviewed. Across 32 arms from 23 published trials, predicted median progression-free survival reached an R-squared of 0.85 (mean absolute error 0.82 months) while objective response rate hit 0.71 (7.3 points), and in seven of eight head-to-head comparisons SCOPE picked the superior arm. Accuracy stands at 90% for prospective calls across more than 30 trials.
From pipeline interest to signed deals
Eighteen of the world’s 20 largest pharma companies appear in Orakl’s pipeline, a figure counting participation rather than signed customers. Early engagements grew into multi-year collaborations, and more than 15 cancer centers are in talks.
The money funds a fivefold increase in data generation and carries the platform from colorectal and pancreatic cancer into lung and gastric disease, plus US and UK teams and predictions across more than 10 drug programs. CEO Fanny Jaulin leads over 40 employees.
